Resmetirom for Fatty Liver: How This Liver-Targeted Therapy Reduces Steatosis and Inflammation

The Burden of Fatty Liver Disease

Metabolic dysfunction–associated steatohepatitis (MASH), previously called NASH, develops when insulin resistance and chronic caloric excess cause liver cells to accumulate fat. This buildup triggers oxidative stress, inflammatory signaling, and progressive fibrosis. For years, despite its growing prevalence, MASH had no approved pharmacologic therapy. Resmetirom, a liver-targeted thyroid hormone receptor-β (THR-β) agonist, represents a significant advancement for patients seeking treatments that address the root causes of fatty liver disease.

THR-β: The Liver’s Metabolic Regulator

THR-β is the thyroid hormone receptor subtype predominantly expressed in the liver and is critical for regulating lipid metabolism, mitochondrial function, and cholesterol handling. In MASH, this pathway is impaired, contributing to fat accumulation, systemic inflammation, and metabolic stagnation. Resmetirom selectively activates THR-β in the liver, restoring lipid metabolism and reducing triglyceride buildup without causing systemic thyroid effects, such as those on the heart, bone, or nervous system.

How Resmetirom Restores Liver Metabolism

By activating THR-β, resmetirom enhances hepatic fatty-acid oxidation and improves mitochondrial efficiency, directly reducing the triglyceride accumulation that drives steatosis. The therapy also modulates lipoprotein metabolism by increasing LDL-receptor expression, lowering LDL cholesterol, and decreasing apolipoprotein B levels. These effects not only improve liver fat content but also reduce cardiovascular risk, which is elevated in patients with fatty liver disease. Beyond metabolic effects, resmetirom diminishes inflammatory signaling and slows the activation of hepatic stellate cells, the main contributors to fibrosis development, addressing both early and progressive stages of liver disease.

Clinical Evidence and Treatment Impact

Clinical trials, including MAESTRO-NASH and MAESTRO-NAFLD-1, have shown that resmetirom significantly reduces liver fat content by week 16 and increases the likelihood of MASH resolution without worsening fibrosis. Some participants also demonstrated improvements in fibrosis itself. Notably, these metabolic and histologic improvements occur even in patients who do not experience significant weight loss, indicating that resmetirom targets hepatic dysfunction directly rather than relying on systemic weight reduction alone.

Health Canada Status

Resmetirom is not currently approved by Health Canada for the treatment of fatty liver disease. At present, the therapy remains investigational, and all available data come from clinical trials rather than real-world use. Health Canada requires comprehensive evidence on safety, efficacy, and long-term outcomes before authorizing new treatments. As a result, resmetirom cannot yet be prescribed in Canada outside of approved studies, and patients should monitor official regulatory updates for any changes in status.

Why This Matters for Patients with MASH

Fatty liver disease often progresses silently, and patients may not experience symptoms until advanced fibrosis or cirrhosis develops. Resmetirom offers a liver-focused approach that addresses the core mechanisms of steatosis, inflammation, and fibrosis, providing hope for slowing or reversing disease progression.

At True North Metabolic, we help patients navigate both approved and emerging therapies for liver and metabolic health. While resmetirom is not yet authorized by Health Canada, we stay up to date on clinical research and regulatory developments. Our goal is to integrate evidence-based strategies, monitor liver function, and optimize metabolic care so that patients are prepared to benefit from new treatments once they become available.

Visit our Metabolic Health and Weight Loss Clinic to learn more.